Overall survival of patients with AML and an intermediate or unfavorable karyotype according to revised MRC criteria. (A) Survival of patients with intermediate compared with unfavorable cytogenetics. (B) Survival of patients with MSK compared with patients with intermediate or unfavorable cytogenetics without MSK. (C) Survival of patients with CK defined as ≥ 3 unrelated abnormalities compared with patients with intermediate or unfavorable cytogenetics without CK. (D) Survival of patients with CK defined as ≥ 4 unrelated abnormalities compared with patients with intermediate or unfavorable cytogenetics without CK. (E) Survival of patients with CK defined as ≥ 5 unrelated abnormalities compared with patients with intermediate or unfavorable cytogenetics without CK. (F) Survival of patients fulfilling definition of CK defined as ≥ 3 unrelated abnormalities and MSK compared with patients with MSK not fulfilling the criteria of CK compared with patients with CK but not MSK compared with patients with neither CK nor MSK. (G) Survival of patients fulfilling definition of CK defined as ≥ 4 unrelated abnormalities and MSK compared with patients with MSK not fulfilling the criteria of CK compared with patients with CK but not MSK compared with patients with neither CK nor MSK.